SFPIA
TGTX icon

Stevens First Principles Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-500
Closed -$8K – 240
2015
Q1 		$8K Buy
+500
New +$7.57K 0.01% 189
2013
Q3 		– Sell
-1,000
Closed -$6K – 235
2013
Q2 		$6K Buy
+1,000
New +$6.41K ﹤0.01% 191

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Stevens First Principles Investment Advisors's TGTX Position: Q2 2015 in Review

Stevens First Principles Investment Advisors sold out of TG Therapeutics (TGTX) in Q2 2015, closing a stake of 500 shares — an estimated $8K sold.

Stevens First Principles Investment Advisors first reported a position in TGTX in Q2 2013 and held it in 2 quarters. The position peaked at $8K in Q1 2015. 90 funds tracked by Wall St. Rank hold TGTX as of Q2 2015.

  • Stevens First Principles Investment Advisors reported no remaining TG Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 500 TG Therapeutics shares in Q2 2015, an estimated $8K.
  • Stevens First Principles Investment Advisors first reported a position in TG Therapeutics in Q2 2013 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's TG Therapeutics position peaked at $8K in Q1 2015.
  • 90 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q2 2015, filed 5 Aug 2015.